D.P.T Vaccine0.5 ml

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed is a vaccine indicated for active booster immunization against tetanus, diphtheria and pertussis. This Vaccine Adsorbed is approved for use as a single dose in persons 10 through 64 years of age

Vaccines, Anti-sera & Immunoglobulin

Diphtheria, Tetanus and Pertussis vaccine­ prepared from diphtheria formol toxoid, tetanus formol toxoid and pertussis vaccine (killed B pertusis not less than 4 IU from not more than 20000 million organism/0.5 ml); 0.5 ml ampoule: Injection.

Child: Under 5 yrs, primary immunisation-3 doses of 0.5 ml vaccine by IM or deep SC injection, each dose at an interval of minimum 4 weeks; Over 5 yrs, not recommended.

Child: Under 5 yrs, primary immunisation-3 doses of 0.5 ml vaccine by IM or deep SC injection, each dose at an interval of minimum 4 weeks; Over 5 yrs, not recommended.

When Diphtheria, Pertussis & Tetanus vaccine was administered concomitantly with trivalent inactivated influenza vaccine (TIV) to adults 19-64 years of age, a lower antibody response was observed for pertactin antigen as compared to Diphtheria, Pertussis & Tetanus vaccine administered alone. Immunosuppressive therapies may reduce the immune response to Diphtheria, Pertussis & Tetanus vaccine. Do not mix this vaccine with any other vaccine in the same syringe or vial

Severe allergic reaction (eg, anaphylaxis) to any component of Diphtheria, Pertussis & Tetanus vaccine or any other diphtheria toxoid, tetanus toxoid and pertussis antigencontaining vaccine. Encephalopathy (eg, coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous pertussis antigen-containing vaccine.

The most common solicited injection site reactions occurring within 0-14 days following vaccination with this were: For Adolescents 11-17 years of age: pain (77.8%), swelling (20.9%), erythema (20.8%). For Adults 18-64 years of age: pain (65.7%), swelling (21.0%), erythema (24.7%).  The most common solicited systemic reactions occurring within 0-14 days following vaccination with this were: For Adolescents 11-17 years of age: headache (43.7%), body ache or muscle weakness (30.4%), tiredness (15.1%). For Adults 18-64 years of age: headache (33.9%), body ache or muscle weakness (21.9%).

Safety and effectiveness of this vaccine have not been established in pregnant women.

For one presentation of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, the tip caps of the prefilled syringes may contain natural rubber latex, which may cause allergic reactions in latex sensitive individuals. If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following a subsequent dose of this vaccineProgressive or unstable neurologic conditions are reasons to defer this vaccination.Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine should not receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed unless at least 10 years have elapsed since the last dose of a tetanus toxoid containing vaccine.Syncope (fainting) can occur in association with administration of injectable vaccines, including Diphtheria, Pertussis & Tetanus vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions.

Vaccines, Anti-sera & Immunoglobulin

Diphtheria, Tetanus and Pertussis vaccine­ prepared from diphtheria formol toxoid, tetanus formol toxoid and pertussis vaccine (killed B pertusis not less than 4 IU from not more than 20000 million organism/0.5 ml); 0.5 ml ampoule: Injection.

Safety and effectiveness of this vaccine have not been established in pregnant women.